---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-038536"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2022-07-11T23:59:59+00:00"
generated_at: "2026-06-24T17:47:16.166654+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Allarity appoints three new directors, expands board from 4 to 6 members

## Summary
- Board size increased to 6; new directors: David Roth (independent), James Cullem (Interim CEO), Thomas Jensen (co-founder, SVP IR).
- David Roth, M.D., brings 25+ years oncology drug development experience; currently CMO of Syros Pharmaceuticals.
- Bylaws amended: stockholder quorum reduced from majority to 33.33% of voting power.
- Independent director annual retainer raised to $50,000; Roth received options for 23,000 shares at $1.28.
- Cullem continues as CEO and Chief Business Officer; Jensen as SVP Investor Relations.

## SEC filing metadata
- accession: 0001213900-22-038536
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2022-07-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390022038536/0001213900-22-038536-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390022038536/ea162649-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-038536
- JSON: https://secwatch.observer/filing/0001213900-22-038536.json
- Plain text: https://secwatch.observer/filing/0001213900-22-038536.txt

## Key facts
- Executive change
  James G. Cullem was appointed as Director at Allarity Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: Class III Director : James G. Cullem, whose term will expire at the Company’s third annual meeting of stockholders to be held after December 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390022038536/0001213900-22-038536-index.htm
- Executive change
  David Roth was appointed as Director at Allarity Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: Class II Director : Dr. David Roth, whose term will expire at the Company’s second annual meeting of stockholders to be held after December 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390022038536/0001213900-22-038536-index.htm
- Executive change
  Thomas Jensen was appointed as Director at Allarity Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: Class I Director : Thomas Jensen, whose term will expire at the Company’s first annual meeting of stockholders held after December 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390022038536/0001213900-22-038536-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.